Fluticasone propionate/salmeterol - GlaxoSmithKline

Drug Profile

Fluticasone propionate/salmeterol - GlaxoSmithKline

Alternative Names: Adoair Aerosol; Adoair Diskus; Advair Diskus; Advair HFA; Anasma Accuhaler; Atmadisc; Fluticasone propionate/salmeterol; Inaladuo; Plusvent Accuhaler; salmeterol xinafoate/fluticasone propionate; Seretide; Seretide Accuhaler; Seretide Diskus; Seretide Evohaler; Seretide MDI; Viani

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glaxo Wellcome SA; GlaxoSmithKline
  • Developer GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Discontinued Rhinitis

Most Recent Events

  • 01 Nov 2016 GlaxoSmithKline completes a phase III trial in Asthma (In Children, In adults, In adolescents) in USA, Argentina, Brazil, Chile, Czech Republic, Germany, South Korea, Mexico, Netherlands, Romania, Russia and Spain (Inhalation, Powder) (NCT02301975)
  • 03 Sep 2016 Additional adverse events data from phase IV trials (AUSTRI and VESTRI) in Asthma presented at the 26th Annual Congress of the European Respiratory Society (ERS - 2016)
  • 01 Apr 2015 GlaxoSmithKline completes a phase III trial in Chronic obstructive pulmonary disease (In adults, In the elderly) in Argentina, Mexico, Russia and Ukraine (NCT01978145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top